Overview

Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder

Status:
Completed

Trial end date:
2018-01-18

Target enrollment:

Participant gender:

Summary

This study is designed to prospectively confirm the efficacy of a fixed-dose regimen of cariprazine 1.5 milligrams (mg)/day or 3 mg/day compared to placebo for treatment of the depressive episode in participants with bipolar I disorder. The safety and tolerability of the fixed-dose regimens will be evaluated.

Phase:

Phase 3

Details

Lead Sponsor:

Forest Laboratories

Treatments:

Cariprazine